AbbVie
ABBV
$208.50
+0.31%
AbbVie is a global pharmaceutical company with a diversified portfolio spanning immunology, oncology, neuroscience, and aesthetics. It is a market leader in immunology with blockbuster drugs Skyrizi and Rinvoq, and has fortified its position through strategic acquisitions like Allergan (aesthetics) and, more recently, Cerevel (neuroscience) and ImmunoGen (oncology). The current investor narrative is dominated by the successful transition away from Humira's patent cliff, with Skyrizi and Rinvoq driving robust growth, while recent news highlights pipeline progress in obesity and Crohn's disease, offset by near-term setbacks like an FDA manufacturing rejection for a wrinkle drug.…
ABBV
AbbVie
$208.50
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating & Thesis: AbbVie is a BUY for value-oriented, income-seeking investors, based on its compelling combination of growth, cash flow, and a discounted valuation that offers significant upside as near-term headwinds abate. This view is anchored by the analyst consensus leaning bullish and an average price target implying over 25% upside from current levels.
Supporting Evidence: The thesis is supported by four key data points: 1) A forward P/E of 12.78x sits below the sector average, indicating undervaluation. 2) Revenue growth remains solid at 10.04% YoY, driven by new blockbusters. 3) Profitability, while volatile, showed a strong recovery with an 84.02% gross margin in Q4 2025. 4) The company's $18.70B TTM free cash flow provides a formidable margin of safety and funds a durable dividend (2.83% yield).
Risks & Conditions: The two biggest risks are prolonged technical weakness eroding investor confidence and competitive pressures slowing the growth of Skyrizi/Rinvoq. This Buy rating would downgrade to Hold if the stock breaks below its 52-week low of $176.57 on sustained volume, or if QoQ revenue growth decelerates below 5%. It would upgrade to a Strong Buy if the forward P/E compresses further toward 11x while growth metrics hold. Based on its forward multiple versus growth and cash flow, the stock is currently undervalued relative to its own prospects and the sector.
Sign up to view all
ABBV 12-Month Price Forecast
The data supports a bullish stance, though confidence is tempered by severe near-term technical damage. The core investment proposition is clear: a market-leading pharmaceutical company with proven blockbuster growth, exceptional cash generation, and a valuation that does not reflect these strengths. The primary path to realizing value is a shift in market sentiment, which will likely be driven by a couple of quarters of clean earnings execution. The stance would be downgraded to neutral if the stock fails to hold the $200 level or if next quarter's revenue growth decelerates meaningfully.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $271.05 and implied upside of +30.0% versus the current price.
Average Target
$271.05
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$167 - $271
Analyst target range
Analyst coverage is robust with 15 firms providing estimates, and recent institutional ratings show a generally bullish sentiment with actions like 'Overweight' from Morgan Stanley and Piper Sandler, and an upgrade from HSBC to 'Buy'. The consensus recommendation leans bullish, and the average revenue target for the next period is approximately $83.93 billion, with an average EPS target of $20.33, which, applied to the forward P/E of 12.78x, implies a target price near $260, representing significant upside from the current $206.60. The target range for estimated revenue is wide, from $82.50 billion to $84.92 billion, and the EPS range is $19.88 to $20.64; the high end of these ranges likely assumes successful pipeline conversions and market share gains for Skyrizi/Rinvoq, while the low end may factor in competitive pressures and regulatory delays. The recent pattern of reiterated 'Overweight' and 'Buy' ratings in Q1 2026, despite the stock's decline, signals analyst conviction in the long-term fundamentals, though the wide target spread on revenue indicates some uncertainty around the exact growth trajectory.
Bulls vs Bears: ABBV Investment Factors
The investment debate for AbbVie centers on a clash between strong fundamental growth and deteriorating market sentiment. The bull case is compelling, anchored by a 10% revenue growth rate, a massive $18.7B FCF engine, a discounted forward P/E of 12.78x, and over 25% implied upside to analyst targets. However, the bear case is visibly dominant in the near term, evidenced by severe technical underperformance, volatile quarterly earnings, and rising competitive threats. The single most important tension is whether the market will soon recognize and reward the company's successful post-Humira transition and robust financials, or if persistent negative momentum, competitive pressures, and pipeline delays will continue to suppress the valuation multiple.
Bullish
- Strong Revenue Growth from New Blockbusters: Q4 2025 revenue grew 10.04% YoY to $16.62B, driven by Skyrizi ($5.01B) and Rinvoq ($2.37B), successfully offsetting Humira's decline. This demonstrates the successful transition from the patent cliff and provides a robust growth foundation.
- Exceptional Free Cash Flow Generation: Trailing twelve-month free cash flow of $18.70 billion is massive, supporting a substantial dividend (2.76 payout ratio) and share repurchases. This financial strength provides significant flexibility for R&D, M&A, and shareholder returns.
- Attractive Forward Valuation: The forward P/E of 12.78x is at a discount to the broader drug manufacturer sector average, which often trades in the mid-teens. This suggests the market is not pricing in the company's growth potential, offering a value opportunity.
- Analyst Conviction and Significant Upside: The consensus analyst price target, implied by a forward P/E of 12.78x and average EPS target of $20.33, is approximately $260. This represents over 25% upside from the current price of $206.60, with recent reiterated 'Buy' and 'Overweight' ratings signaling conviction.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 7.36% over the past 3 months, severely underperforming the S&P 500 (+4.14%), with a relative strength of -22.18 over one year. Trading near 44% of its 52-week range ($176.57 to $244.81) confirms persistent negative momentum and investor skepticism.
- Volatile and Depressed Profitability Metrics: Quarterly net income has been highly volatile, from $1.82B in Q4 2025 to just $0.19B in Q3 2025. The trailing P/E of 96.26x, though distorted by one-time items, reflects this earnings weakness and creates a misleadingly expensive headline valuation.
- Increasing Competitive Threats: Recent FDA approval of Johnson & Johnson's oral psoriasis drug Icotyde introduces new competition for blockbuster Skyrizi. This exemplifies the constant pipeline risk in immunology, where AbbVie's key growth drivers face encroachment.
- Regulatory and Operational Setbacks: An FDA rejection in April 2026 for a wrinkle drug (TrenibotE) due to manufacturing issues highlights near-term pipeline execution risks. While not a science failure, such delays can weigh on sentiment and delay revenue streams.
ABBV Technical Analysis
The stock is in a sustained downtrend, with a 1-year price change of +6.86% significantly underperforming the S&P 500's +29.04%, as indicated by a -22.18 relative strength. As of the latest close of $206.60, the price is trading at approximately 44% of its 52-week range ($176.57 to $244.81), positioning it much closer to the low, which suggests a potential value opportunity but also reflects persistent negative momentum. Recent momentum has been decisively negative, with the stock down -3.90% over the past month and -7.36% over the past three months, both periods showing severe underperformance versus the market (SPY +9.98% and +4.14%, respectively), confirming the downtrend's acceleration. Key technical support is clearly defined at the 52-week low of $176.57, while resistance sits at the 52-week high of $244.81; a breakdown below support would signal a continuation of the bearish trend, whereas a recovery above the $230 level is needed to suggest stabilization. The stock's beta of 0.364 indicates it is approximately 64% less volatile than the broader market, which is unusually low for a large-cap pharma and may reflect its defensive, dividend-oriented characteristics amid the current sell-off.
Beta
0.30
0.30x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$177-$245
Price range past year
Annual Return
+10.9%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +1.0% | +8.2% |
| 3m | -8.4% | +9.0% |
| 6m | -10.3% | +10.5% |
| 1y | +10.9% | +26.5% |
| ytd | -9.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
Revenue growth remains solid, with Q4 2025 revenue of $16.62 billion representing a 10.04% year-over-year increase, and the quarterly trend shows sequential growth from $13.34B in Q1 to $16.62B in Q4. Segment data reveals Skyrizi as the dominant growth driver at $5.01 billion, followed by Rinvoq at $2.37 billion, successfully offsetting the decline of legacy Humira ($1.25 billion). Profitability is strong but showed volatility in 2025; Q4 2025 net income was $1.82 billion with a robust gross margin of 84.02%, a significant recovery from the negligible net income of $0.19 billion in Q3 2025 which had a gross margin of 66.38%. The full-year net margin stands at 6.91% per valuation data, indicating the company is solidly profitable, though margins have fluctuated quarter-to-quarter due to acquisition-related costs and R&D investments. The balance sheet and cash flow position are exceptionally strong, with trailing twelve-month free cash flow of $18.70 billion supporting a substantial dividend (payout ratio of 2.76) and share repurchases. The debt-to-equity ratio is a negative -21.12, an accounting artifact likely due to significant retained earnings or intangible assets creating negative shareholder equity, but the company's massive FCF generation provides ample liquidity and financial flexibility, as evidenced by a current ratio of 0.67.
Quarterly Revenue
$16.6B
2025-12
Revenue YoY Growth
+0.10%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$18.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given the positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is elevated at 96.26x, while the forward P/E is a much lower 12.78x; this massive gap implies the market expects a dramatic earnings recovery, as the trailing figure is distorted by one-time charges or acquisition amortization. Compared to industry averages, AbbVie's forward P/E of 12.78x is at a discount to the broader 'Drug Manufacturers' sector, which often trades in the mid-teens, suggesting the market is pricing in lower growth or lingering concerns over pipeline execution and patent expirations. Historically, the stock's own trailing P/E has been highly volatile, ranging from as low as 14.8x in late 2021 to the current 96.3x; the current level is near the extreme top of its historical band, but this is misleading as it reflects depressed trailing earnings rather than excessive optimism, with the forward multiple suggesting a more normalized valuation.
PE
96.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -3572x~551x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: AbbVie's primary financial risk is earnings volatility, as evidenced by net income swinging from $1.82B in Q4 2025 to $0.19B in Q3 2025, which complicates valuation and investor confidence. While free cash flow generation is robust at $18.7B TTM, the company carries a high dividend payout ratio of 2.76, which is unsustainable long-term and requires consistent FCF. Operationally, revenue remains concentrated in immunology (Skyrizi & Rinvoq), making growth dependent on these products' continued market share gains amidst new competition like J&J's recently approved psoriasis drug.
Market & Competitive Risks: The stock's low beta of 0.364 suggests it is behaving defensively, but its severe underperformance (-22.18 relative strength vs. SPY) indicates company-specific de-rating risk. The forward P/E of 12.78x, while a discount to peers, could compress further if growth decelerates or if the market applies a permanent discount due to pipeline concerns. Competitive disruption is a clear and present risk, with recent news highlighting new entrants in psoriasis and the constant threat in oncology and neuroscience, sectors where AbbVie has made recent acquisitions (Cerevel, ImmunoGen).
Worst-Case Scenario: The worst-case scenario involves a combination of Skyrizi/Rinvoq growth deceleration due to intensified competition, pipeline failures in key new areas like obesity, and a broader market sell-off hitting defensive sectors. This could trigger a re-rate to a deeper value multiple, pushing the stock toward its 52-week low of $176.57. From the current price of $206.60, this represents a realistic downside of approximately -14.5%. A breach of this support could see further declines, potentially matching the stock's recent max drawdown of -19.23%.
FAQ
The key risks are: 1) Competitive: New drug approvals (e.g., J&J's psoriasis pill) threatening Skyrizi/Rinvoq growth, the primary revenue drivers. 2) Operational: Earnings volatility, as seen in the swing from $1.82B to $0.19B net income between recent quarters, and FDA regulatory setbacks like the recent manufacturing rejection. 3) Market/Sentiment: Severe technical downtrend with the stock underperforming the S&P 500 by over 22% in the past year, indicating persistent negative momentum that can become self-fulfilling. 4) Financial: A high dividend payout ratio of 2.76, though currently supported by strong FCF, requires vigilant monitoring.
The 12-month forecast is a base case target range of $230 to $260 (55% probability), aligning with the analyst average target. This assumes steady execution with 8-10% revenue growth. The bull case (30% probability) sees a re-rating to $260-$275 on superior execution and pipeline wins. The bear case (15% probability) involves a test of the 52-week low near $176 if competition intensifies and sentiment worsens. The most likely outcome is the base case, predicated on AbbVie's proven ability to generate cash and grow its new blockbuster franchises as planned.
ABBV is undervalued based on forward-looking metrics. The trailing P/E of 96.26x is misleading due to one-time charges; the relevant forward P/E is 12.78x. This is a discount to the broader drug manufacturer sector, which often trades in the mid-teens, despite AbbVie's 10% revenue growth and industry-leading free cash flow margins. Compared to its own history, the current forward multiple is at the lower end of its range, suggesting the market is pricing in excessive pessimism around competition and growth sustainability.
For investors with a 12-18 month horizon and a tolerance for near-term volatility, ABBV presents a compelling risk/reward opportunity. The stock is undervalued based on a forward P/E of 12.78x, offers a secure 2.83% dividend yield backed by massive free cash flow, and has over 25% upside to the average analyst target. The biggest downside risk is a continuation of the technical downtrend toward the 52-week low of $176.57. It is a good buy for value and income investors, but less suitable for short-term traders given its current negative momentum.
ABBV is primarily suitable for a long-term investment horizon of 2-3 years or more. Its low beta of 0.364 and reliable dividend make it a defensive holding, while the multi-year growth runway for Skyrizi and Rinvoq requires time to unfold. The current technical weakness and negative momentum make it a poor candidate for short-term trading. A minimum holding period of 12-18 months is suggested to allow for the valuation gap to close and for the investment thesis based on cash flow and growth to play out.